Allogeneic BMT in patients above 45 years of age : a single center experience
Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT i...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2001-04, Vol.27 (7), p.723-726 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 726 |
|---|---|
| container_issue | 7 |
| container_start_page | 723 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 27 |
| creator | LYSAK, D KOZA, V VOKURKA, S JINDRA, P VOZOBULOVA, V SCHUTZOVA, M FISER, J CERNA, K KARAS, M SKOPEK, P SVOJGROVA, M |
| description | Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT in our institution over the preceding 4 years. Pretransplant conditioning consisted of Bu/CY2, GVHD prophylaxis of a combination of cyclosporine and "short" methotrexate. At present 54% of patients remain alive (with a median follow-up 44 months), the probability of survival at 5 years is 53% (5-year DFS 78%). The 5-year survival probability in the control group of younger patients is 53% (P = 0.8003). Main causes of death were GVHD (4 patients, 10%), relapse (5 patients, 13%) and infection (6 patients, 15%). The incidence of acute GVHD grade II-IV was 51% (grade III-IV 0% patients), the incidence of chronic GVHD 49% (limited 18% and extensive 31% patients). Our results suggest that allogeneic BMT can be performed in patients above the age of 45 years with acceptable morbidity and mortality, especially if a family HLA matched donor is available. |
| doi_str_mv | 10.1038/sj.bmt.1702851 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70843495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>998065871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-b73b7503ff12635bd903d43a51c4c49737647bc0efce5b5fe85d8d96cf0341d83</originalsourceid><addsrcrecordid>eNqF0U1rFEEQBuBGFLNGrx6lMeJtNlXTn-MtCfEDEnKJ56anp3qZZXZm7Z4N5t_bSwYUQTzV5amXKl7G3iKsEYQ9z9t1u5vXaKC2Cp-xFUqjKyW0es5WUGtbCaGbE_Yq5y0ASgnqJTtBFBoQ6xW7vRiGaUMj9YFf3t7zfuR7P_c0zpn7dnogLhV_JJ8ynyL3G-KfuOe5HzcD8VAYJU4_95TKSqDX7EX0Q6Y3yzxl3z9f3199rW7uvny7uripggQ7V60RrVEgYsRaC9V2DYhOCq8wyCAbI4yWpg1AMZBqVSSrOts1OkQQEjsrTtnHp9x9mn4cKM9u1-dAw-BHmg7ZGbBSyEb9F6IFU1uUBZ79BbfTIY3lCVdrWaPVAuqi3v9ToS5Hq-YYtX5CIU05J4pun_qdT48OwR1Lc3nrSmluKa0svFtSD-2Out98aamADwvwOfghJj-GPv8Rq_B44C9l_Zwx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216647594</pqid></control><display><type>article</type><title>Allogeneic BMT in patients above 45 years of age : a single center experience</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>LYSAK, D ; KOZA, V ; VOKURKA, S ; JINDRA, P ; VOZOBULOVA, V ; SCHUTZOVA, M ; FISER, J ; CERNA, K ; KARAS, M ; SKOPEK, P ; SVOJGROVA, M</creator><creatorcontrib>LYSAK, D ; KOZA, V ; VOKURKA, S ; JINDRA, P ; VOZOBULOVA, V ; SCHUTZOVA, M ; FISER, J ; CERNA, K ; KARAS, M ; SKOPEK, P ; SVOJGROVA, M</creatorcontrib><description>Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT in our institution over the preceding 4 years. Pretransplant conditioning consisted of Bu/CY2, GVHD prophylaxis of a combination of cyclosporine and "short" methotrexate. At present 54% of patients remain alive (with a median follow-up 44 months), the probability of survival at 5 years is 53% (5-year DFS 78%). The 5-year survival probability in the control group of younger patients is 53% (P = 0.8003). Main causes of death were GVHD (4 patients, 10%), relapse (5 patients, 13%) and infection (6 patients, 15%). The incidence of acute GVHD grade II-IV was 51% (grade III-IV 0% patients), the incidence of chronic GVHD 49% (limited 18% and extensive 31% patients). Our results suggest that allogeneic BMT can be performed in patients above the age of 45 years with acceptable morbidity and mortality, especially if a family HLA matched donor is available.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1702851</identifier><identifier>PMID: 11360112</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Actuarial Analysis ; Age ; Age Factors ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Bone marrow ; Bone marrow transplantation ; Bone Marrow Transplantation - methods ; Bone Marrow Transplantation - mortality ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Cause of Death ; Cyclosporins ; Female ; Graft vs Host Disease - classification ; Graft-versus-host reaction ; Hematologic and hematopoietic diseases ; Hematologic Neoplasms - mortality ; Hematologic Neoplasms - therapy ; Histocompatibility antigen HLA ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Methotrexate ; Middle Aged ; Morbidity ; Prophylaxis ; Retrospective Studies ; Stem cell transplantation ; Survival ; Survival Rate ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation Conditioning ; Transplantation, Homologous - methods ; Transplantation, Homologous - mortality</subject><ispartof>Bone marrow transplantation (Basingstoke), 2001-04, Vol.27 (7), p.723-726</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Apr 2001</rights><rights>Macmillan Publishers Limited 2001.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-b73b7503ff12635bd903d43a51c4c49737647bc0efce5b5fe85d8d96cf0341d83</citedby><cites>FETCH-LOGICAL-c408t-b73b7503ff12635bd903d43a51c4c49737647bc0efce5b5fe85d8d96cf0341d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1051186$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11360112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LYSAK, D</creatorcontrib><creatorcontrib>KOZA, V</creatorcontrib><creatorcontrib>VOKURKA, S</creatorcontrib><creatorcontrib>JINDRA, P</creatorcontrib><creatorcontrib>VOZOBULOVA, V</creatorcontrib><creatorcontrib>SCHUTZOVA, M</creatorcontrib><creatorcontrib>FISER, J</creatorcontrib><creatorcontrib>CERNA, K</creatorcontrib><creatorcontrib>KARAS, M</creatorcontrib><creatorcontrib>SKOPEK, P</creatorcontrib><creatorcontrib>SVOJGROVA, M</creatorcontrib><title>Allogeneic BMT in patients above 45 years of age : a single center experience</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT in our institution over the preceding 4 years. Pretransplant conditioning consisted of Bu/CY2, GVHD prophylaxis of a combination of cyclosporine and "short" methotrexate. At present 54% of patients remain alive (with a median follow-up 44 months), the probability of survival at 5 years is 53% (5-year DFS 78%). The 5-year survival probability in the control group of younger patients is 53% (P = 0.8003). Main causes of death were GVHD (4 patients, 10%), relapse (5 patients, 13%) and infection (6 patients, 15%). The incidence of acute GVHD grade II-IV was 51% (grade III-IV 0% patients), the incidence of chronic GVHD 49% (limited 18% and extensive 31% patients). Our results suggest that allogeneic BMT can be performed in patients above the age of 45 years with acceptable morbidity and mortality, especially if a family HLA matched donor is available.</description><subject>Actuarial Analysis</subject><subject>Age</subject><subject>Age Factors</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Bone Marrow Transplantation - mortality</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Cause of Death</subject><subject>Cyclosporins</subject><subject>Female</subject><subject>Graft vs Host Disease - classification</subject><subject>Graft-versus-host reaction</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematologic Neoplasms - mortality</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Prophylaxis</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Homologous - methods</subject><subject>Transplantation, Homologous - mortality</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0U1rFEEQBuBGFLNGrx6lMeJtNlXTn-MtCfEDEnKJ56anp3qZZXZm7Z4N5t_bSwYUQTzV5amXKl7G3iKsEYQ9z9t1u5vXaKC2Cp-xFUqjKyW0es5WUGtbCaGbE_Yq5y0ASgnqJTtBFBoQ6xW7vRiGaUMj9YFf3t7zfuR7P_c0zpn7dnogLhV_JJ8ynyL3G-KfuOe5HzcD8VAYJU4_95TKSqDX7EX0Q6Y3yzxl3z9f3199rW7uvny7uripggQ7V60RrVEgYsRaC9V2DYhOCq8wyCAbI4yWpg1AMZBqVSSrOts1OkQQEjsrTtnHp9x9mn4cKM9u1-dAw-BHmg7ZGbBSyEb9F6IFU1uUBZ79BbfTIY3lCVdrWaPVAuqi3v9ToS5Hq-YYtX5CIU05J4pun_qdT48OwR1Lc3nrSmluKa0svFtSD-2Out98aamADwvwOfghJj-GPv8Rq_B44C9l_Zwx</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>LYSAK, D</creator><creator>KOZA, V</creator><creator>VOKURKA, S</creator><creator>JINDRA, P</creator><creator>VOZOBULOVA, V</creator><creator>SCHUTZOVA, M</creator><creator>FISER, J</creator><creator>CERNA, K</creator><creator>KARAS, M</creator><creator>SKOPEK, P</creator><creator>SVOJGROVA, M</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20010401</creationdate><title>Allogeneic BMT in patients above 45 years of age : a single center experience</title><author>LYSAK, D ; KOZA, V ; VOKURKA, S ; JINDRA, P ; VOZOBULOVA, V ; SCHUTZOVA, M ; FISER, J ; CERNA, K ; KARAS, M ; SKOPEK, P ; SVOJGROVA, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-b73b7503ff12635bd903d43a51c4c49737647bc0efce5b5fe85d8d96cf0341d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Actuarial Analysis</topic><topic>Age</topic><topic>Age Factors</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Bone Marrow Transplantation - mortality</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Cause of Death</topic><topic>Cyclosporins</topic><topic>Female</topic><topic>Graft vs Host Disease - classification</topic><topic>Graft-versus-host reaction</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematologic Neoplasms - mortality</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Prophylaxis</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Homologous - methods</topic><topic>Transplantation, Homologous - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LYSAK, D</creatorcontrib><creatorcontrib>KOZA, V</creatorcontrib><creatorcontrib>VOKURKA, S</creatorcontrib><creatorcontrib>JINDRA, P</creatorcontrib><creatorcontrib>VOZOBULOVA, V</creatorcontrib><creatorcontrib>SCHUTZOVA, M</creatorcontrib><creatorcontrib>FISER, J</creatorcontrib><creatorcontrib>CERNA, K</creatorcontrib><creatorcontrib>KARAS, M</creatorcontrib><creatorcontrib>SKOPEK, P</creatorcontrib><creatorcontrib>SVOJGROVA, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LYSAK, D</au><au>KOZA, V</au><au>VOKURKA, S</au><au>JINDRA, P</au><au>VOZOBULOVA, V</au><au>SCHUTZOVA, M</au><au>FISER, J</au><au>CERNA, K</au><au>KARAS, M</au><au>SKOPEK, P</au><au>SVOJGROVA, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allogeneic BMT in patients above 45 years of age : a single center experience</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>27</volume><issue>7</issue><spage>723</spage><epage>726</epage><pages>723-726</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT in our institution over the preceding 4 years. Pretransplant conditioning consisted of Bu/CY2, GVHD prophylaxis of a combination of cyclosporine and "short" methotrexate. At present 54% of patients remain alive (with a median follow-up 44 months), the probability of survival at 5 years is 53% (5-year DFS 78%). The 5-year survival probability in the control group of younger patients is 53% (P = 0.8003). Main causes of death were GVHD (4 patients, 10%), relapse (5 patients, 13%) and infection (6 patients, 15%). The incidence of acute GVHD grade II-IV was 51% (grade III-IV 0% patients), the incidence of chronic GVHD 49% (limited 18% and extensive 31% patients). Our results suggest that allogeneic BMT can be performed in patients above the age of 45 years with acceptable morbidity and mortality, especially if a family HLA matched donor is available.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>11360112</pmid><doi>10.1038/sj.bmt.1702851</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2001-04, Vol.27 (7), p.723-726 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70843495 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; SpringerLink Journals - AutoHoldings |
| subjects | Actuarial Analysis Age Age Factors Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone marrow Bone marrow transplantation Bone Marrow Transplantation - methods Bone Marrow Transplantation - mortality Bone marrow, stem cells transplantation. Graft versus host reaction Cause of Death Cyclosporins Female Graft vs Host Disease - classification Graft-versus-host reaction Hematologic and hematopoietic diseases Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Histocompatibility antigen HLA Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Methotrexate Middle Aged Morbidity Prophylaxis Retrospective Studies Stem cell transplantation Survival Survival Rate Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation Conditioning Transplantation, Homologous - methods Transplantation, Homologous - mortality |
| title | Allogeneic BMT in patients above 45 years of age : a single center experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T00%3A40%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allogeneic%20BMT%20in%20patients%20above%2045%20years%20of%20age%20:%20a%20single%20center%20experience&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=LYSAK,%20D&rft.date=2001-04-01&rft.volume=27&rft.issue=7&rft.spage=723&rft.epage=726&rft.pages=723-726&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1702851&rft_dat=%3Cproquest_cross%3E998065871%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216647594&rft_id=info:pmid/11360112&rfr_iscdi=true |